文献速递银屑病与炎症性皮肤病

替拉珠单抗治疗中重度头皮斑块状银屑病的3b期研究

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
PubMed 文献 · J Am Acad Dermatol · 2024-03-28

这项3b期随机双盲安慰剂对照研究评估了替拉珠单抗治疗中重度头皮斑块状银屑病的疗效与安全性。患者分别接受替拉珠单抗100 mg或安慰剂在第0周和第4周给药。第16周时,替拉珠单抗组49.4%达到主要终点,安慰剂组仅7.3%,且未出现新的安全性信号。

要点

  • 替拉珠单抗100 mg在第16周使49.4%患者达到头皮IGA应答,安慰剂组为7.3%。
  • 第16周PSSI 90应答率替拉珠单抗组为60.7%,安慰剂组为4.9%。
  • 未发生与治疗相关的严重不良事件。

核心结论

  • 替拉珠单抗治疗中重度头皮斑块状银屑病有效,且未观察到新的安全性信号。

研究设计与样本

  • 3b期、随机、双盲、安慰剂对照研究(NCT03897088),纳入中重度斑块状银屑病累及头皮的患者,替拉珠单抗组89例,安慰剂组82例。

主要发现

  • 第16周IGA mod 2011(头皮)应答率替拉珠单抗组49.4%,安慰剂组7.3%。
  • 第12周IGA mod 2011(头皮)应答率替拉珠单抗组46.1%,安慰剂组4.9%。
  • 第16周PSSI 90应答率替拉珠单抗组60.7%,安慰剂组4.9%。
  • 第12周PSSI 90应答率替拉珠单抗组48.3%,安慰剂组2.4%。

关键数值与推荐

  • 主要终点为第16周IGA mod 2011(头皮)评分为「清除」或「几乎清除」且较基线改善≥2分。
  • 关键次要终点包括第12周和第16周PSSI 90应答率以及第12周IGA mod 2011(头皮)应答率。
  • 入组标准为IGA mod 2011(头皮)≥3、PSSI≥12且头皮受累面积≥30%。

临床怎么用

  • 替拉珠单抗100 mg在第0周和第4周给药可考虑用于中重度头皮银屑病。
  • 短期数据显示头皮症状改善显著,安全性可接受。

局限性

  • 仅报告了短期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scalp psoriasis is common and difficult to treat. OBJECTIVE: To evaluate efficacy and safety of tildrakizumab for the treatment of scalp psoriasis. METHODS: In this Phase 3b, randomized, double-blind, placebo (PBO)-controlled study (NCT03897088), patients with moderate-to-severe plaque psoriasis affecting the scalp (Investigator Global Assessment modified [IGA mod] 2011 [scalp] ≥3, Psoriasis Scalp Severity Index [PSSI] ≥12, ≥30% scalp surface area affected) received tildrakizumab 100 mg or PBO at W0 and W4. The primary endpoint was IGA mod 2011 (scalp) score of "clear" or "almost clear" with ≥2-point reduction from baseline at W16 (IGA mod 2011 [scalp] response). Key secondary endpoints were PSSI 90 response at W12 and W16 and IGA mod 2011 (scalp) response at W12. Safety was assessed from adverse events. RESULTS: Of patients treated with tildrakizumab (n = 89) vs PBO (n = 82), 49.4% vs 7.3% achieved IGA mod 2011 (scalp) response at W16 (primary endpoint) and 46.1% vs 4.9% at W12; 60.7% vs 4.9% achieved PSSI 90 response at W16 and 48.3% vs 2.4% at W12 (all P < .00001). No serious treatment-related adverse events occurred. LIMITATIONS: Only short-term data are presented. CONCLUSION: Tildrakizumab was efficacious for the treatment of scalp psoriasis with no new safety signals.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gebauer K, Spelman L, Yamauchi PS, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. J Am Acad Dermatol. 2024. PMID: 38554938. doi:10.1016/j.jaad.2024.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。